Actavis U.S., the United States commercial and marketing arm of the collective generic pharmaceuticals group Actavis Group (ICEX: ACT), today announced that it hold received classification from the U.S. Food & Drug Administration (FDA) to marketplace Ranitidine Oral Solution USP. Due to Actavis’s first-to-file prestige, the FDA has granted Actavis a 180-day marketing [...]
Entries from October 2008
Actavis Receives Approval For Ranitidine Syrup In The U.S.
October 11th, 2008 · No Comments
Tags: Uncategorized
Gastrointestinal Graft-versus-Host Disease – OrBec(r) Pivotal Phase 3 Clinical Trial Results Published In Journal ‘Blood’ Part 2
October 5th, 2008 · No Comments
“This be an defining, validate milestone all for DOR and its orBec(r) program. Ãâà Publication of these facts encircled by Blood, one of the furthermost prominent peer-review review in hematology, further documents the persuasive sanctuary profile and long-term subsistence pro of orBec(r) in theÃâà analysis of GI GVHD,” stated Christopher J. Schaber, Ph.D., President [...]
Tags: Uncategorized